| |
|
Safety and Efficacy at 48 Weeks After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients With Risk Factors for TDF Use
|
| |
| |
AASLD November 8-12, 2019, Boston, MA
Reported by Jules Levin
Maria Buti,1 Pietro Lampertico,2 Young-Suk Lim,3 Kosh Agarwal,4 Scott Fung,5 Tak Yin Owen Tsang,6 Magdy Elkashab,7 Jia-Horng Kao,8 Jose Luis Calleja-Panero,9 Mandana Khalili,10 Natarajan Ravendhran,11 Susanna Tan,12 John F. Flaherty,12 Anuj Gaggar,12 Audrey Lau,12 George Wu,12 Hie-Won Hann,13 Calvin Pan,14 Hyung Jun Kim,15 Patrick Kennedy,16 Henry Lik-Yuen Chan17
1Hospital Universitario Vall d'Hebron and Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; 2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy; 3Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 4Institute of Liver Studies, King's College Hospital, London, UK; 5Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Ontario, Canada; 6Princess Margaret Hospital, Hong Kong; 7Toronto Liver Centre, Toronto; 8Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; 9Hospital Universitario Puerta de Hierro-Majadahonda, Spain; 10University of California San Francisco; 11Digestive Disease Associates, Catonsville, MD; 12Gilead Sciences, Inc., Foster City, CA; 13Thomas Jefferson University Hospital, Philadelphia, PA; 14Flushing, NY; 15Chung-Ang University College of Medicine, Seoul; 16Barts Health NHS Trust, London; 17The Chinese University of Hong Kong
| |
| |
| |
|
|
|
